Tissue Plasminogen Activator for Acute Ischemic Stroke.¶
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. (1995). Tissue Plasminogen Activator for Acute Ischemic Stroke. New England Journal of Medicine, 333(24), 1581-1587.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Kairos
- Medicine and clinical intervention. Therapeutic windows in stroke care, sepsis resuscitation, staging-dependent treatment, and circadian drug dosing — same intervention, different state, different outcome.
This sourceEstablishes the time-limited therapeutic window: thrombolysis within three hours of onset improves outcome despite hemorrhage risk — the canonical state-gated clinical window (also anchoring the broader therapeutic-window claim).
Supported in partVerified against the work's full text
The NINDS trial supports only the stroke time-window example; sepsis, staging-dependent therapy and circadian dosing are not covered.
“treatment with intravenous t-PA within three hours of the onset of ischemic stroke improved clinical outcome at three months.”
- Medicine and clinical intervention. Therapeutic windows in stroke care, sepsis resuscitation, staging-dependent treatment, and circadian drug dosing — same intervention, different state, different outcome.
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:e50ad8fc683f · see in the full table